Want to join the conversation?
David Risinger of Morgan Stanley asks about Enbrel, ex-US, what percentage of revenue is in countries where biosimilars are launching in 2016. $PFE said that on the Enbrel business, the company does not have an exact figure on hand, but said more than 50% of the ex-US business would be in the European Union.
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.